The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has been granted Good Manufacturing Practice (GMP) Certification for its new production facilities in Mont-Saint-Guibert. Certification was granted by the Federal Agency for Medicines and Health Products (FAMHP), the authority responsible for the quality, safety and efficacy of medicines and health products in Belgium.
GMPs are regulatory requirements that provide guidelines for necessary processes, procedures and documentation to assure that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use. The FAMHP inspected Cardio3 BioSciences' Mont-Saint-Guibert facilities to certify such continued compliance.
The Mont-St-Guibert production facilities are used in the manufacture and testing of Cardio3 BioSciences' lead product C3BS-CQR-1, a regenerative therapy currently in development for the treatment of heart failure. C3BS-CQR-1 is expected to enter a Phase III study in 2012.
Dr Christian Homsy, CEO of Cardio3BioSciences, said: "We've followed GMP guidelines from the start of our activities and are very pleased to have demonstrated, via this recent audit and registration and also our recent ISO certification for our cardiac catheter work, our continuing commitment to quality practices. Gaining GMP certification from the health authorities is also a key step for Cardio3 BioSciences ahead of our planned Phase III trial for C3BS-CQR-1, a product we believe offers a potentially revolutionary new approach for the treatment of heart failure, one of the world's most significant unmet medical needs."
Heart attack recovery enhanced by human stem cell spheroids, study shows